Novo Nordisk ROE 2006-2018 | NVO

Current and historical return on equity (ROE) values for Novo Nordisk (NVO) over the last 10 years.
Novo Nordisk Annual ROE - Return on Equity
2017 76.54
2016 83.78
2015 74.22
2014 65.72
2013 59.16
2012 52.75
2011 43.29
2010 40.36
2009 30.09
2008 29.25
2007 26.48
2006 21.44
2005 21.19
Novo Nordisk Quarterly ROE - Return on Equity
Q2 2018 21.07
Q1 2018 24.30
Q4 2017 17.45
Q3 2017 20.81
Q2 2017 20.55
Q1 2017 25.20
Q4 2016 18.62
Q3 2016 23.72
Q2 2016 23.41
Q1 2016 25.36
Q4 2015 17.22
Q3 2015 19.45
Q2 2015 21.33
Q1 2015 30.76
Q4 2014 15.21
Q3 2014 17.12
Q2 2014 19.08
Q1 2014 19.23
Q4 2013 14.60
Q3 2013 16.40
Q2 2013 19.05
Q1 2013 17.70
Q4 2012 14.31
Q3 2012 15.89
Q2 2012 17.06
Q1 2012 14.41
Q4 2011 11.87
Q3 2011 11.68
Q2 2011 11.18
Q1 2011 11.72
Q4 2010 11.06
Q3 2010 11.28
Q2 2010 10.90
Q1 2010 9.73
Q4 2009 6.87
Q3 2009 8.16
Q2 2009 8.78
Q1 2009 8.75
Q4 2008 6.35
Q3 2008 8.28
Q2 2008 4.78
Q1 2008 6.98
Q4 2007 3.20
Q3 2007 6.59
Q2 2007 10.91
Q1 2007 5.74
Q4 2006 5.87
Q3 2006 6.24
Q2 2006 5.99
Q1 2006 4.48
Q4 2005 4.56
Q3 2005 6.98
Q2 2005 6.92
Q1 2005 4.87
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.970B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62